CN101848708B - 皮质类固醇用于制备治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻的药物 - Google Patents

皮质类固醇用于制备治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻的药物 Download PDF

Info

Publication number
CN101848708B
CN101848708B CN2008801149548A CN200880114954A CN101848708B CN 101848708 B CN101848708 B CN 101848708B CN 2008801149548 A CN2008801149548 A CN 2008801149548A CN 200880114954 A CN200880114954 A CN 200880114954A CN 101848708 B CN101848708 B CN 101848708B
Authority
CN
China
Prior art keywords
epothilone
cancer
diarrhea
prednisolone
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801149548A
Other languages
English (en)
Chinese (zh)
Other versions
CN101848708A (zh
Inventor
A·R·约赫里
P·M·J·麦克希伊
D·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101848708A publication Critical patent/CN101848708A/zh
Application granted granted Critical
Publication of CN101848708B publication Critical patent/CN101848708B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN2008801149548A 2007-11-09 2008-10-15 皮质类固醇用于制备治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻的药物 Expired - Fee Related CN101848708B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98663507P 2007-11-09 2007-11-09
US60/986,635 2007-11-09
PCT/US2008/079936 WO2009061587A1 (en) 2007-11-09 2008-10-15 Corticosteroids to treat epothilone or epothilone derivative induced diarrhea

Publications (2)

Publication Number Publication Date
CN101848708A CN101848708A (zh) 2010-09-29
CN101848708B true CN101848708B (zh) 2013-01-02

Family

ID=40087318

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801149548A Expired - Fee Related CN101848708B (zh) 2007-11-09 2008-10-15 皮质类固醇用于制备治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻的药物

Country Status (11)

Country Link
US (1) US20100267682A1 (enExample)
EP (1) EP2222286A1 (enExample)
JP (1) JP2011503075A (enExample)
KR (1) KR20100096077A (enExample)
CN (1) CN101848708B (enExample)
AU (1) AU2008325016A1 (enExample)
BR (1) BRPI0820338A2 (enExample)
CA (1) CA2703792A1 (enExample)
MX (1) MX2010005119A (enExample)
RU (1) RU2010123028A (enExample)
WO (1) WO2009061587A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN109790584A (zh) * 2016-09-27 2019-05-21 梅奥医学教育及研究基金会 用于评价和治疗癌症的材料和方法
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
US10705435B2 (en) 2018-01-12 2020-07-07 Globalfoundries Inc. Self-referencing and self-calibrating interference pattern overlay measurement
US11686576B2 (en) 2020-06-04 2023-06-27 Kla Corporation Metrology target for one-dimensional measurement of periodic misregistration
US11796925B2 (en) 2022-01-03 2023-10-24 Kla Corporation Scanning overlay metrology using overlay targets having multiple spatial frequencies
US12032300B2 (en) 2022-02-14 2024-07-09 Kla Corporation Imaging overlay with mutually coherent oblique illumination
US12422363B2 (en) 2022-03-30 2025-09-23 Kla Corporation Scanning scatterometry overlay metrology
US12487190B2 (en) 2022-03-30 2025-12-02 Kla Corporation System and method for isolation of specific fourier pupil frequency in overlay metrology
US12235588B2 (en) 2023-02-16 2025-02-25 Kla Corporation Scanning overlay metrology with high signal to noise ratio

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1988904A (zh) * 2004-07-26 2007-06-27 诺瓦提斯公司 埃坡霉素组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231894A (zh) * 1998-04-14 1999-10-20 陈水清 止泻栓
DE60229922D1 (de) * 2001-03-19 2009-01-02 Novartis Ag Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
CN100553634C (zh) * 2002-10-11 2009-10-28 达纳-法伯癌症研究公司 用于治疗多发性骨髓瘤的埃坡霉素衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1988904A (zh) * 2004-07-26 2007-06-27 诺瓦提斯公司 埃坡霉素组合

Also Published As

Publication number Publication date
WO2009061587A1 (en) 2009-05-14
US20100267682A1 (en) 2010-10-21
CA2703792A1 (en) 2009-05-14
AU2008325016A1 (en) 2009-05-14
CN101848708A (zh) 2010-09-29
RU2010123028A (ru) 2011-12-20
JP2011503075A (ja) 2011-01-27
BRPI0820338A2 (pt) 2017-05-02
KR20100096077A (ko) 2010-09-01
EP2222286A1 (en) 2010-09-01
MX2010005119A (es) 2010-05-27

Similar Documents

Publication Publication Date Title
CN101848708B (zh) 皮质类固醇用于制备治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻的药物
AU2013205648B2 (en) Combination treatment
TWI688387B (zh) 二氫槲皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
JP6145778B2 (ja) 特発性炎症性筋疾患の予防又は治療剤
JP5416327B2 (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
ZA200409137B (en) Combinations comprising epothilones and pharmaceutical uses thereof
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
KR20040091141A (ko) 알도스테론 수용체 길항물질 및 니코틴산 또는 니코틴산유도체의 혼합물
EP1408977B1 (en) A combination therapy for the treatment of heart failure
TWI289060B (en) Pharmaceutical composition for improving the recovery of post-stroke patients
US20080262071A1 (en) Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
CN118526513A (zh) 紫花前胡苷在制备减轻铂类药物肌毒性的药物中的应用
AU658169B2 (en) Pharmaceutical composition containing granisetron and dexamethasone
ES2281775T3 (es) Metodo para tratar insuficiencia renal.
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
KR20040107481A (ko) 알도스테론 수용체 길항물질 및 담즙산 격리제의 혼합물
US20160296574A1 (en) Ephedra alata extracts and methods of use thereof
WO2022054965A1 (en) Compound for use in the treatment of dry mouth
US20080312250A1 (en) Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide
EP1793818A2 (en) Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
US20030139430A1 (en) Use of organic compounds
KR20250102046A (ko) 다주코릴란트를 이용한 근위축성 측삭경화증의 치료
WO2023016551A1 (zh) 用于治疗或预防抗宿主病的吡咯并六元杂芳物
CN119816307A (zh) 包含flt3抑制剂的癌症组合疗法
KR20040107482A (ko) 알도스테론 수용체 길항물질 및 피브르산 유도체의 혼합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130102

Termination date: 20131015